Back to top
more

Adverum Biotechnologies (ADVM)

(Delayed Data from NSDQ)

$6.70 USD

6.70
124,893

-0.02 (-0.30%)

Updated Aug 6, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?

GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.

    What's in Store for Intercept (ICPT) This Earnings Season?

    Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).

      Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?

      Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.

        Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?

        CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.

          Is a Beat in Store for Adverum (ADVM) This Earnings Season?

          Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.

            Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%

            Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.

              What's in the Cards for Adverum (ADVM) This Earnings Season?

              Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.

                Adverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher

                Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.

                  Marinus Stock Surges on Successful Phase II Epilepsy Study

                  Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.

                    Is Adverum Biotechnologies an Incredible Momentum Stock? 3 Reasons Why ADVM Will Be Tough to Beat

                    Adverum Biotechnologies (ADVM) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.

                      What's in the Cards for Adverum (ADVM) this Earnings Season?

                      Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.

                        What's in Store for Adverum (ADVM) in Q1 Earnings?

                        Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.

                          Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?

                          Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.